Literature DB >> 20950119

5-Fluorouracil/Leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma: a clinical experience.

Lisa Podolsky, Melissa Oh, Pochi R Subbarayan, Dido Francheschi, Alan Livingstone, Bach Ardalan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20950119     DOI： 10.3109/0284186X.2010.524934

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  5 in total

1.  Arsenic trioxide targets MTHFD1 and SUMO-dependent nuclear de novo thymidylate biosynthesis.

Authors:  Elena Kamynina; Erica R Lachenauer; Aislyn C DiRisio; Rebecca P Liebenthal; Martha S Field; Patrick J Stover
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-06       Impact factor: 11.205

Review 2.  In the war against solid tumors arsenic trioxide needs partners.

Authors:  Pochi R Subbarayan; Bach Ardalan
Journal:  J Gastrointest Cancer       Date:  2014-09

3.  The antitumor effect of arsenic trioxide on hepatocellular carcinoma is enhanced by andrographolide.

Authors:  Xuhua Duan; Tengfei Li; Xinwei Han; Jianzhuang Ren; Pengfei Chen; Hao Li; Shaojun Gong
Journal:  Oncotarget       Date:  2017-06-27

4.  Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.

Authors:  Fatima Rangwala; Kevin P Williams; Ginger R Smith; Zainab Thomas; Jennifer L Allensworth; H Kim Lyerly; Anna Mae Diehl; Michael A Morse; Gayathri R Devi
Journal:  BMC Cancer       Date:  2012-09-10       Impact factor: 4.430

Review 5.  Arsenic trioxide as a novel anti-glioma drug: a review.

Authors:  Yi Fang; Zhen Zhang
Journal:  Cell Mol Biol Lett       Date:  2020-09-24       Impact factor: 5.787
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.